Related Experiment Videos
Signaling pathways activated by daunorubicin
1INSERM E9910, Institut Claudius Régaud, Toulouse, France. laurent@icr.fnclcc.fr
Abstract:
The anthracycline daunorubicin is widely used in the treatment of acute nonlymphocytic leukemia. The drug has, of course, been the object of intense basic research, as well as preclinical and clinical study. As reviewed in this article, evidence stemming from this research clearly demonstrates that cell response to daunorubicin is highly regulated by multiple signaling events, including a sphingomyelinase-initiated sphingomyelin-ceramide pathway, mitogen-activated kinase and stress-activated protein/c-Jun N-terminal kinase activation, transcription factors such as nuclear factor kappa B, as well as the Fas/Fas-ligand system. These pathways are themselves influenced by a number of lipid products (diacylglycerol, sphingosine-1 phosphate, and glucosyl ceramide), reactive oxygen species, oncogenes (such as the tumor suppressor gene p53), protein kinases (protein kinase C and phosphoinositide-3 kinase), and external stimuli (hematopoietic growth factors and the extracellular matrix). In light of the complexity and diversity of these observations, a comprehensive review has been attempted toward the understanding of their individual implication (and regulation) in daunorubicin-induced signaling. (Blood. 2001;98:913-924)
Insights
Cell response to daunorubicin, a leukemia drug, is complex. Multiple signaling pathways, including sphingomyelin-ceramide and kinase activation, regulate its effects.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Daunorubicin is a key anthracycline chemotherapy agent for acute nonlymphocytic leukemia.
- Understanding daunorubicin's cellular mechanisms is crucial for optimizing its therapeutic use.
Purpose of the Study:
- To comprehensively review the signaling events regulating cellular response to daunorubicin.
- To elucidate the complex interplay of pathways involved in daunorubicin-induced signaling.
Main Methods:
- Review of existing basic, preclinical, and clinical research on daunorubicin.
- Analysis of signaling pathways, including sphingolipid metabolism, kinase activation, and transcription factors.
- Examination of the influence of various molecular and cellular factors on daunorubicin response.
Main Results:
- Cellular response to daunorubicin is intricately regulated by multiple signaling pathways.
- Key pathways include the sphingomyelinase-initiated sphingomyelin-ceramide pathway, MAPK/SAPK/JNK activation, NF-κB, and the Fas/Fas-ligand system.
- These pathways are modulated by lipids, reactive oxygen species, oncogenes (e.g., p53), protein kinases, and external stimuli.
Conclusions:
- Daunorubicin's effects are mediated by a complex network of signaling events.
- Understanding these regulatory mechanisms is essential for advancing leukemia treatment strategies.
- Further research into these pathways can lead to improved daunorubicin efficacy and reduced toxicity.